Seasonal affective disorder is a type of depression which occurs usually with the season change. It occurs mostly in women and in the age group of 15 to 55 years during winters due to reducing light exposure to sunlight or to the people who live far away from equator where daylight hours are very short.
Strategic launches of products and expansion of businesses undertaken by market players:
The market is segmented on the basis of type as fall and winter sad, spring and summer sad, others; diagnosis as physical exams, lab tests, psychological evaluation; treatment as phototherapy, medications, psychotherapy, counseling; end user as hospital, clinics, academic institutes, medical research centers.; distribution channel as hospital pharmacies, retail pharmacies and drug stores, online pharmacies.
“According to Data Bridge Market Research, Global Seasonal Affective Disorder Market is expected to growing with a steady CAGR of 4.5% during the forecast period of 2017 to 2024”
Some of the major players operating in market are Janssen Pharmaceuticals, Inc., Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc., Sanofi, Eli Lilly and Company, Biogen, Bristol-Myers Squibb Company, Baxter, Novartis AG, Shire, AstraZeneca, Beurer GmbH, Koninklijke Philips N.V., Lumie, Verilux, Inc., AbbVie Inc., ALLARGAN, F. Hoffmann-La Roche Ltd., Henry Schein, Inc. among others.
With the focus of authorities of different regions on promotion of genetic drugs that can be helpful for the patients suffering from seasonal affective disorder, manufacturers of different pharmaceutical domain are not just providing drugs, but going various innovations to improve the quality of the drug supplied to their customers. Physicians are doing certain experiments to cure the problem without getting prone to genetic drugs.
Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/
Global Seasonal Affective Disorder Market - Industry Trends and Forecast to 2024